EU says people vaccinated with AstraZeneca should be able to travel to US

The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.

AstraZeneca Covid-19 vaccine, AstraZeneca
AstraZeneca's Covid-19 vaccine | Photo: Bloomberg
Reuters BRUSSELS
2 min read Last Updated : Sep 21 2021 | 7:31 PM IST
The European Commission said on Tuesday it would make sense for the United States to allow travel by people vaccinated with the AstraZeneca COVID-19 shots, although existing U.S. guidance already authorises those travellers.

On Monday, the White House said it would lift restrictions from November that bar EU citizens, including those fully vaccinated, from traveling to the United States.

"We believe the AstraZeneca vaccine is safe," Eric Mamer, a spokesperson for the EU Commission, told a news conference.

"From our point of view, obviously it would make sense for people who have been vaccinated with AstraZeneca to be able to travel," the spokesperson added, noting that this, however, was a decision for the U.S. authorities.

A spokeswoman for the U.S. Centers for Disease Control and Prevention (CDC) said that it currently considers people to be fully vaccinated, and therefore able to travel by air to the U.S., if they have received any of the FDA-authorized vaccines or shots approved by the World Health Organization, which include AstraZeneca's.

The regulatory U.S. Food and Drug Administration has so far authorised for use the COVID-19 vaccines produced by Pfizer/BioNTech , Moderna and Johnson & Johnson, but is still reviewing the AstraZeneca shot.

The WHO has authorised the AstraZeneca vaccine, including the version made in Europe. The shot is also approved for use in the 27 EU countries where about 70 million doses have been administered cumulatively, according to public data.

The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.

Most EU countries do not accept foreign nationals vaccinated with shots which are not authorised at EU level.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusEuropean CommissionAstraZeneca

Next Story